BioSpace News Archive

The industry analysis report is considered a valuable source of information about the global Tissue Contact Probe Ablators industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Lupin Pharmaceuticals Inc., (Lupin), and Exeltis USA Inc. announced a promotional agreement for Exeltis to promote SOLOSEC® along with Exeltis’ existing line of Women’s Health products, further enhancing value to OBGYNs and their patients.

Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and Epic Sciences, Inc., a leading liquid biopsy diagnostic company, announce they are collaborating to incorporate multi-omic profiling in Biosplice’s clinical oncology programs, including Cirtuvivint (SM08502).

During the recent surge in Omicron cases, Premier Medical Laboratory Services (PMLS) reported a 733% increase in tests being sent to them for processing of results.

In addition to sales growth analysis versus 2020, we are including sales growth versus 2019 as 2019 provides a more normal baseline for comparison given the variability caused by the COVID-19 pandemic throughout 2020.

Participants include a syndicate of existing and new shareholders Contributes to total of $10.1 million in new equity financing for January, 2022.

Kaman Composites – Vermont, Inc., an indirect, wholly owned subsidiary of Kaman Corporation, announces the expansion of its medical imaging program through the recent new partnership with Mirion Technologies, a major medical equipment manufacturer.

Electromed, Inc. today announced that it will issue its financial results press release for the fiscal 2022 second quarter ended December 31, 2021, on Tuesday, February 8, 2022 after the close of the stock market, and host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.

HaemaLogiX Ltd (HaemaLogiX), and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered into an agreement to manufacture the next clinical batch (cGMP) of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab.

Quipt Home Medical Corp. today announced its fourth quarter and fiscal year 2021 financial results and operational highlights and filing of its annual financial statements.